This site is for healthcare professionals. If you are a member of the public or a patient then please visit our Colonoscopy site.

Reminder Service

PLENVU® is generally well-tolerated1-3

PLENVU® was significantly better tolerated than 2L and 4L PEG7

Study design

Mean tolerability score from 0 to 10*7



Adapted from Maida M, et al. 20207

96.5% of patients
thought the tolerability of
PLENVU® was acceptable7


81.1% and 86.3%
treated with 2L and 4L PEG,

*Tolerability was evaluated using a semi-quantitative scale with a score ranging from 0 to 10 (0 represented the worst level of tolerability, and 10 represented the best level of tolerability).
†Sufficient tolerability was defined as a score ≥6.
All treatments were administered using afternoon/afternoon dosing or afternoon/morning dosing.
AE: adverse event.

PLENVU® has a comparable safety profile to other PEG bowel preparations1,4-6

The common adverse events associated with PLENVU® are vomiting, nausea and dehydration4

Please refer to the Summary of Product Characteristics for further information on the safety profile of PLENVU®

Clinical trials

In total,
5 in 6 patients had
no treatment-related
AEs when treated
with PLENVU®

There were
no serious

Most reported
AEs were mild
to moderate1–3

Rates of treatment-related AEs in the safety populations from the MORA, DAYB and NOCT clinical trials1–3



  • 11.5% with PLENVU® evening/morning dosing (30 out of 262 patients)
  • 14.9% with PLENVU® morning/morning dosing (40 out of 269 patients)
  • 7.6% with MOVIPREP® (PEG 3350 + sodium ascorbate + ascorbic acid +sodium sulfate + electrolytes) evening/morning dosing (20 out of 263 patients)



  • 11.9% with PLENVU® evening/evening dosing (28 out of 235 patients)
  • 4.1% with NaPic + MgCit morning/afternoon dosing (10 out of 241 patients)



  • 14.9% with PLENVU® evening/morning dosing (39 out of 262 patients)
  • 9.4% with trisulfate evening/morning dosing (25 out of 265 patients)


AE: Adverse event.

Who can you prescribe PLENVU® for?

PLENVU® can be used without dose adjustments in a wide range of patients4

PLENVU® is indicated in adults for bowel cleansing prior to any procedure requiring a clean bowel4

Patients with IBD can receive PLENVU® but it should be used with caution with severe acute IBD4

No special dosage adjustment is deemed necessary in patients with mild to moderate renal impairment. Patients with mild to moderate renal impairment were included in clinical studies. PLENVU® should be used with caution in patients with severe renal impairment4

No special dosage adjustment is deemed necessary in patients with mild to moderate hepatic impairment. Patients with elevated liver function tests were included in clinical studies4

ESGE recommendation

The ESGE strongly recommend using high volume or low volume PEG-based bowel preparations in patients with IBD.8

ESGE: European Society of Gastrointestinal Endoscopy, IBD: inflammatory bowel disease.

GL-GE-PLV-2100024. July 2021.

Adverse events should be reported to your regulatory agency. Adverse events should also be reported to either your local distributor, Norgine Limited, Norgine House, Moorhall Road, Harefield, Uxbridge, Middlesex, UB9 6NS, United Kingdom or by emailing